ArticleClinical and experimental vaccine research2025
Evaluation of oral and injectable liposome-based vaccines with synthesized lipid for Japanese encephalitis virus in Sprague-Dawley rats.
Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogens of the human central nervous system-the major viral pathogens.Journal of neurovirology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Japanese Encephalitis Virus (JEV) is a mosquito-borne flavivirus that causes severe neurological complications and high mortality rates in Asia. Developing vaccines is crucial for controlling its spread. Liposomes, as advanced drug delivery systems, have demonstrated promise in reducing systemic toxicity and enhancing drug penetration across the blood-brain barrier. Given these advantages, this study aimed to evaluate the immunoglobulin G (IgG) antibody response to JEV antigen administered via injection and liposome-based oral delivery. Materials and Methods: The liposome-based vaccine used in this study was formulated from a custom-synthesized lipid to enhance the vaccine's efficacy. The rats were divided into 3 groups: a control group, a liposome-based injectable vaccine group, and a liposome-based oral vaccine group. Blood samples were collected at 3 and 5 weeks post-administration to measure IgG antibody levels. Results: As expected, the control group exhibited no immune response. In contrast, liposome-based oral and injectable vaccine groups showed considerable results. The liposome-based injectable vaccine group demonstrated a strong increase in IgG levels, and the liposome-based oral vaccine group exhibited a moderate but notable rise. At 5 weeks, antibody levels in the control group returned to baseline, whereas the vaccinated groups maintained elevated levels. Conclusion: The injectable formulation induced a stronger immune response; however, the oral formulation showed potential as an alternative. These findings suggest that refinement of the oral formulation may provide practical advantages such as ease of administration, non-invasiveness, and improved logistics. Such features could potentially contribute to broader immunization efforts, including those aimed at global disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.